Healthcare holding company · Delaware
We're building a vertically integrated healthcare platform across the U.S. and Mexico, bringing diagnostics, distribution, pharmacy, hospital care, and government contracting under one roof.
PeopleInnovationInvestmentImpact
What we do
Aivital Health Capital Inc. is a healthcare holding company that acquires, owns, operates, and invests in businesses across medical technology, pharmaceutical distribution, medical equipment, and healthcare infrastructure in the U.S., Mexico, and select international markets.
We target cash-flowing operating companies with hard assets and roll them up into a single, integrated value chain. The result is one platform with a foothold on both sides of the U.S.–Mexico border.
We source and acquire established healthcare operators in the U.S. and Mexico: medical equipment and drug distributors, labs, imaging, pharmacies, hospitals, and a government contracting business.
We bring them together into one continuum of care and supply: lab and diagnostics, distribution, retail pharmacy, hospital care, and government procurement.
We fund growth through Series B shares, offered via a fractional economic interest token, and distribute consolidated free cash flow to investors.
The platform
Each company plays a distinct role. Together, they cover the full continuum, from diagnosis to government procurement, in Mexico and the U.S.
Stage 1
3 reference labs and 1 imaging center
Medical Tech Biotecnología
Stage 2
Medical equipment and pharmaceuticals in Mexico and Texas
Multiequipos y Medicamentos
Enzem Medical
Stage 3
Retail pharmacy network plus an anchor hospital
Farmacias Punto Médico
Punto Médico Hospital
Stage 4
Mexican federal government contracts
Multimed
Target portfolio
Distribution · Mexico
Distribution · Texas
Diagnostics · Mexico
Care delivery · Mexico
Care delivery · Mexico
Government contracting · Mexico
A note on portfolio information. This site describes what each target company does, its strategic role, and how it fits the platform. It does not include revenue, EBITDA, valuations, or financial projections. Financial information will be shared only with accredited and qualified investors during due diligence, under an NDA.
Investment thesis
Our thesis is built on companies that are already up and running, with hard assets and recurring demand. This isn't a single-asset bet. It's a phased vertical integration strategy in which each acquisition feeds the next.
Demand for drugs, diagnostics, medical equipment, and hospital care is driven by patient need, not consumer spending. That helps keep the platform's cash flow steady across economic cycles.
Pairing Mexican operations with a U.S. platform in Texas lets the group source, distribute, and bill on both sides of the border.
When the lab, distributor, pharmacy, and hospital are under one roof, margin that used to go to third parties stays in-house and becomes distributable cash flow.
Federal bidding capability opens a high-volume channel for the group's own inventory through public-sector healthcare supply contracts.
The pharmacy model is already running at 3 locations and is designed to scale to 200, making retail the platform's most repeatable growth engine.
The Series B preferred return sets a clear payout order: operating costs first, then reserves, then the investor's target return, and finally residual cash flow to shareholders.
Investment platform · Series B
Aivital issues Series B shares with a preferred return and offers them to accredited investors through an economic interest token. Each token represents a fractional economic interest in one Series B share and is backed by a special purpose vehicle (SPV) that holds the shares and receives cash flow from the portfolio companies.
Represents a fractional interest in Series B shares of Aivital Health Capital Inc. It carries no voting or control rights, only economic rights to the preferred return and to Series B's share of residual distributions.
An issuing SPV holds the Series B shares and collects cash flow from the acquired companies. The token is backed by the SPV, which is the investor's legal counterparty.
Total token supply is fixed and released in tranches as each acquisition closes. The offering is open only to accredited and qualified investors who clear KYC/AML.
| Issuer | Aivital Health Capital Inc., a Delaware corporation. |
|---|---|
| Share class | Series B shares, with a preferred return in the distribution waterfall. |
| Target annual return | 25% per year on Series B shares (target only; not guaranteed). |
| Distribution frequency | Monthly (approx. 1.88%) or quarterly (approx. 5.70%), equivalent to the 25% annual target. |
| Token unit | 1 token = a fractional economic interest in 1 Series B share. |
| Supply | Fixed supply, issued in tranches as each acquisition closes. |
| Vehicle | SPV that holds the Series B shares and receives portfolio cash flow. |
| Technical standard | ERC-20 (Ethereum token standard). |
| Investor onboarding | Mandatory KYC/AML and wallet whitelisting; lock-up and vesting periods apply. |
| Reporting | Audited quarterly reporting. |
| Secondary market | Planned for a later phase, subject to applicable regulations. |
| Eligible investors | Accredited and qualified investors only. Not a public offering. |
Closing on the platform's target companies.
Equipment and capacity for clinical operations.
Build-out toward 200 Punto Médico locations.
Liquidity to bid on and fulfill public-sector contracts (Multimed).
Token platform, KYC/AML, audit, and legal.
Allocations are targets and may shift based on the timing of each acquisition closing.
Distribution waterfall
Consolidated free cash flow is paid out in a set order. Series B receives its preferred return before any residual cash flow goes to shareholders.
First, cash covers operating expenses and overhead at the holding company and the operating companies.
Next, the group funds its cash reserve and sets aside maintenance capital for lab, imaging, pharmacy, and hospital assets.
Then, cash goes to the Series B preferred return, up to the 25% annual target. This is a target, not a guarantee.
Once the first three tiers are satisfied, any remaining cash is split between Series A and Series B shareholders under the terms of each share class.
Sources of return
Series B distributions are funded by the consolidated free cash flow of the acquired companies, not by new investor capital.
Compliance
Tokenization is subject to Mexican regulation (the Fintech Law and CNBV rules) and to U.S. securities laws. The offering is limited to accredited and qualified investors, is not a public offering, and requires KYC/AML screening.
Risk factors
Growth roadmap
We're executing in phases: first the legal, accounting, and compliance foundation; then the initial Series B raise; then the acquisitions and integrations that build out the platform.
Incorporate the holding company, stand up its legal, accounting, and compliance framework, and design the token and issuing SPV.
Raise seed capital and close the initial Series B round with accredited and qualified investors.
Acquire Multiequipos y Medicamentos (Mexico) and Enzem Medical (Texas), establishing the group's distribution arms and its entry into the U.S. market.
Integrate Medical Tech Biotecnología (3 reference labs, 1 imaging center) and consolidate the 3 Punto Médico pharmacies.
Launch the federal contracting channel through Multimed and integrate Punto Médico Hospital as the platform's clinical anchor.
Scale the pharmacy network to 200 locations, complete an external audit, begin quarterly reporting, and open a secondary market for the token.
Phases reflect our planned sequence and may change as each deal progresses.
Leadership
Aivital Health Capital Inc. is led by its founders, who run the company day to day and serve as its authorized representatives.
President & CEO
Leads the company's acquisition strategy, investor relations, and Series B capital structure, and serves as its authorized representative.
[email protected]
Chief Operating Officer
Oversees group operations and post-acquisition integration, running the lab, distribution, pharmacy, and hospital businesses as one platform.
[email protected]Investors
Series B offering documents are available to accredited and qualified investors after KYC/AML verification. Submit a request and a member of our team will follow up directly.
